SHAREHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 17, 2021	May 20, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock		$ 0	$ 7,020
Unamortized issuance costs		$ 2,001		$ 3,849
Warrants exercised (in shares)			400,000
Common shares issued (in shares)			400,000
Warrants outstanding			$ 0
Zyla Life Sciences | Iroko | Warrant Agreements
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise aggregate ownership percentage maximum threshold						49.00%
Zyla Life Sciences | Money market funds | Zyla Life Sciences
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price, number of shares outstanding, per share (in dollars per share)						$ 0.0016
At The Market Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate offering price					$ 25,000
Stock offering, shares sold (in shares)		2,463,637
Stock offering, purchase price (in dollars per share)		$ 3.02
Stock offering, gross proceeds		$ 7,400
Stock offering, net proceeds		7,000
Additional Paid-In Capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Induced exchange of convertible notes, gross		28,300
Convertible notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized issuance costs		1,600
6.5% Convertible Senior Secured Notes due 2027 | Convertible notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock	$ 10,500
Induced exchange of convertible notes (in shares)	7,000,000
Unamortized issuance costs		$ 1,600